,

Hydroxychloroquine and COVID-19

Hydroxychloroquine and COVID-19 - هیدروکسی کلروکین و درمان کرونا

The anti-inflammatory drug hydroxychloroquine does not significantly reduce admission to intensive care or death in patients hospitalized with pneumonia due to covid-19, finds a study from France published by The BMJ today. Adverse events were more common in those receiving the drug.

Release date: 15 May 2020

Source: BMJ

You might also like
Concern about loved ones might motivate people to mask up, get vaccine - نگرانی نسبت به عزیزان باعث ایجاد انگیزه در زدن ماسک و انجام واکسیناسیون می شود Concern about loved ones might motivate people to mask up, get vaccine
Masks Not Enough to Stop COVID19 Spread Without Distancing - استفاده از ماسک بدون فاصله گذاری برای کنترل کرونا کافی نیست Masks Not Enough to Stop COVID-19’s Spread Without Distancing
Physical inactivity linked to more severe COVID19 infection and death - بی تحرکی و مرگ کرونایی Physical inactivity linked to more severe COVID-19 infection and death
COVID-19 children - کودکان ویروس کرونا COVID-19 may be less common in children
Genomic Analysis Reveals Many Animal Species May Be Vulnerable to SARS-CoV-2 Infection - حیوانات می توانند ناقل کرونا شوند Many Animal Species May Be Vulnerable to SARS-CoV-2
If relaxed too soon, physical distancing measures might have been all for naught - کاهش زودهنگام محدودیت های فاصله گذاری اجتماعی، نتیجه، اصلا فاصله گذاری اجتماعی انجام نشده If relaxed too soon, physical distancing measures might have been all for naught